Indicated for the treatment of enterobiasis, ascariasis, clonorchiasis, taeniasis, toxocariasis, and trichinellosis.
Each film-coated Albezi tablet contains 200 mg of the active ingredient Albendazole.
Excipients: Lactose, magnesium carbonate, croscarmellose sodium, sodium bicarbonate, sodium lauryl sulfate, povidone, sodium starch glycolate, talc, magnesium stearate, coating powder.
Enterobiasis
Ancylostomiasis and Necatoriasis
Hymenolepiasis
Taeniasis
Strongyloidiasis
Ascariasis
Trichocephalosis
Clonorchiasis
Opisthorchiasis
Cutaneous Larva Migrans
Giardiasis in children
Cystic echinococcosis
Alveolar echinococcosis
Neurocysticercosis
Hepatic fascioliasis
Gnathostomiasis
Trichinellosis
Toxocariasis
Retinal pathology
Pregnancy
Breastfeeding
Hypersensitivity to any component of the product
During treatment with Albezi, a mild elevation in liver enzymes may occur, which usually resolves after discontinuation. Liver function tests should be performed before each treatment cycle and every 2 weeks during treatment. If liver enzyme levels increase more than twice the normal level, Albezi should be discontinued and may be resumed after normalization.
Albezi may cause a mild, reversible decrease in white blood cell count. Peripheral blood count should also be monitored before each treatment cycle and every 2 weeks during treatment. In the case of leukopenia, treatment should be discontinued.
In patients with neurocysticercosis, headaches may occur due to increased intracranial pressure caused by the death of the parasites. In such cases, immediate corticosteroid and anti-seizure therapy is required.
Oral or intravenous corticosteroids are recommended during the first week of treatment to prevent a potential rise in intracranial pressure.
Not recommended for children under 1 year of age.
No side effects of albendazole have been reported that impair psychomotor performance or the ability to drive or operate machinery.
Albezi is contraindicated during pregnancy and lactation.
Women of childbearing potential should use effective contraception during the entire course of treatment and for at least 1 month after the last dose due to the risk of systemic infections.
Albezi should be taken with food, preferably at the same time each day.
If a 3-week course does not result in recovery, a repeat course is necessary.
If the patient cannot swallow the whole tablet, it may be crushed and taken with water.
| Infection | Age | Dosage and Duration |
|---|---|---|
| Enterobiasis, Ancylostomiasis, Necatoriasis, Ascariasis, Trichocephalosis | Adults and children over 2 years | 400 mg once daily / single dose |
| Children aged 1–2 years | 200 mg once daily / single dose | |
| Strongyloidiasis, Taeniasis, Hymenolepiasis | Adults and children over 2 years | 400 mg once daily / for 3 days In hymenolepiasis, repeat course after 10–21 days if needed |
| Clonorchiasis, Opisthorchiasis | Adults and children over 2 years | 400 mg twice daily / for 3 days |
| Cutaneous Larva Migrans | Adults and children over 2 years | 400 mg once daily / for 1–3 days |
| Giardiasis | Children aged 2–12 years | 400 mg once daily / for 5 days |
Higher doses and longer therapy are required. Dosage is determined individually based on age, body weight, and severity of the infection.
Use of high doses is not recommended in children under 6 years.
For patients weighing over 60 kg: 400 mg twice daily
For patients under 60 kg: 15 mg/kg/day divided into 2 doses
Maximum daily dose: 800 mg
| Infection | Treatment Duration |
|---|---|
| Cystic echinococcosis | 28 days per cycle. In non-operable cases: 3 cycles of 28 days each with 14-day breaks. Before surgery: 2 cycles of 28 days with 14-day breaks. If surgery was within 14 days or cysts are viable post-op: 2 more cycles post-surgery with 14-day breaks. |
| Alveolar echinococcosis | 28-day cycles. Second cycle starts after 2-week break. May continue for several months or years. |
| Neurocysticercosis | 7 to 31 days. Repeat treatment allowed after a 2-week break. |
| Hepatic fascioliasis | 400 mg once daily / for 10 days |
| Gnathostomiasis | 400 mg once daily / for 10–20 days |
| Trichinellosis, Toxocariasis | 400 mg twice daily / for 5–10 days |
Shelf life: 3 years
Store at below 30°C (86°F)
Keep out of reach of children
